Norditropin Daily denied as non-formulary by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Denied Norditropin as Non-Formulary

A "non-formulary" denial on Norditropin from UnitedHealthcare is not a clinical rejection — it is a PDL tiering decision routed through OptumRx, UHC's pharmacy benefit manager. UnitedHealthcare's Commercial PDL preferences rotate among the seven somatropin products (Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Zomacton) and the preferred agent shifts with contracting cycles. When Norditropin lands in non-preferred status, OptumRx auto-rejects the claim at point-of-sale with a reject code 75 (prior auth required) or 70 (product/service not covered) even when the underlying medical-policy PA for somatropin is already approved.

The critical distinction prescribers miss: the Medical Benefit Drug Policy "Human Growth Hormone – Somatropin" controls clinical eligibility (Pediatric GHD, Adult GHD per ITT <5 ng/mL, Prader-Willi, SGA, ISS with height SDS <-2.25, Transition Phase), but the OptumRx formulary controls product selection. A successful Adult GHD PA approved at the medical-policy level still bounces if the patient is dispensed Norditropin instead of the currently preferred pen. Step therapy to the preferred somatropin is the default expectation.

## The Correct Appeal Vector

Do not appeal this as a medical-necessity denial — appeal it as a formulary exception request under 29 CFR §2590.136 and the plan's exception process. Submit through OptumRx's PA portal (not the medical benefits PA line) citing one of three grounds: (1) documented intolerance or contraindication to the preferred somatropin device or excipient (Norditropin FlexPro contains phenol; Genotropin MiniQuick contains m-cresol — excipient hypersensitivity is a legitimate exception); (2) device-specific functional need (dexterity, dose-titration granularity at 0.025 mg increments unique to Norditropin FlexPro); or (3) prior treatment failure on the preferred agent with documented suboptimal IGF-1 response.

For ERISA-governed commercial plans, invoke 29 CFR §2560.503-1(g) and demand the specific formulary rule and the comparative clinical rationale UHC used to deem Norditropin non-essential while preferring an alternative somatropin — somatropins are pharmacologically equivalent recombinant rDNA proteins, so a non-formulary classification grounded purely in rebate economics is vulnerable. For fully-insured plans, escalate via state DOI parity complaint; for self-funded ERISA plans, preserve the record for §502(a)(1)(B) review. Medicare Advantage enrollees use the §423.578 tiering exception pathway with a 72-hour standard / 24-hour expedited turnaround.

## Tactical Tip

Before filing, pull the patient's current OptumRx preferred somatropin list directly from the member portal (it changes quarterly) and have the endocrinologist's PA letter explicitly state the IGF-1 titration target and why the device's dose increments matter — generic "medically necessary" letters lose. Pair the exception request with a same-day peer-to-peer through OptumRx clinical (not UHC medical) — the reviewer is a different clinician than the one who handles GHD medical-necessity PAs.